As of 2025-09-18, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -3.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 175.59 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -46.80 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 1.9x - 6.1x | 2.4x |
| Forward P/E multiples | 8.7x - 13.5x | 11.0x |
| Fair Price | (4.57) - (3.25) | (3.54) |
| Upside | -359.4% - -284.4% | -301.1% |
| Date | EV/EBITDA |
| 2025-09-12 | -3.68 |
| 2025-09-11 | -3.77 |
| 2025-09-10 | -3.78 |
| 2025-09-09 | -3.77 |
| 2025-09-08 | -3.72 |
| 2025-09-05 | -3.77 |
| 2025-09-04 | -3.91 |
| 2025-09-03 | -3.94 |
| 2025-09-02 | -3.91 |
| 2025-09-01 | -3.99 |
| 2025-08-29 | -3.91 |
| 2025-08-28 | -3.94 |
| 2025-08-27 | -3.91 |
| 2025-08-26 | -3.94 |
| 2025-08-25 | -4.12 |
| 2025-08-22 | -4.24 |
| 2025-08-21 | -4.17 |
| 2025-08-20 | -4.18 |
| 2025-08-19 | -4.25 |
| 2025-08-18 | -4.21 |
| 2025-08-15 | -4.15 |
| 2025-08-14 | -4.09 |
| 2025-08-13 | -4.02 |
| 2025-08-12 | -3.85 |
| 2025-08-11 | -3.87 |
| 2025-08-08 | -3.89 |
| 2025-08-07 | -3.88 |
| 2025-08-06 | -3.89 |
| 2025-08-05 | -3.93 |
| 2025-08-04 | -3.92 |
| 2025-08-01 | -3.94 |
| 2025-07-31 | -3.96 |
| 2025-07-30 | -4.09 |
| 2025-07-29 | -4.06 |
| 2025-07-28 | -4.04 |
| 2025-07-25 | -3.81 |
| 2025-07-24 | -3.79 |
| 2025-07-23 | -3.63 |
| 2025-07-22 | -3.52 |
| 2025-07-21 | -3.52 |
| 2025-07-18 | -3.67 |
| 2025-07-17 | -3.39 |
| 2025-07-16 | -3.36 |
| 2025-07-15 | -3.24 |
| 2025-07-14 | -3.18 |
| 2025-07-11 | -3.24 |
| 2025-07-10 | -3.26 |
| 2025-07-09 | -3.30 |
| 2025-07-08 | -3.26 |
| 2025-07-07 | -3.30 |